Mono Vaccines (Epstein-Barr virus) Market, By Age group (Adult, and Pediatrics), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)- Trends, Analysis and Forecast till 2034

Mono Vaccines (Epstein - Barr virus) Market was valued at US$ 7.5 billion in 2024 and is projected to grow at a CAGR of 5.40% to reach US$ 12.6 billion by 2034.

Mononucleosis is a disease caused Epstein-Barr virus an infectious illness, which is also known as mono or kissing disease. Mononucleosis virus is generally spread through saliva and also can be spread through sharing drinks or utensils.Further, Human herpesvirus 4 is the causative agent of mono/ kissing disease. Moreover, Epstein–Barr virus is the most common type of virus in humans and is one of eight known human herpes virus types in the herpes family.

The symptoms of mononucleosis disease are common as the other illness, hence it’s difficult to detect. The mononucleosis can be confirmed with blood test that detects antibodies.

                           For More Report Details, Download Free Sample PDF

Increasing research and development by various pharmaceutical companies and universities for development of novel Mono Vaccines or Epstein - Barr virus vaccines is expected to foster the Mono Vaccines (Epstein - Barr virus) Market.

Additionally, high prevalence of Epstein - Barr virus is expected to increase demand for its vaccines and this is expected to drive the mono vaccines (Epstein - Barr virus) market growth in the near future.

Mono Vaccines (Epstein - Barr virus) Market is segmented based on Type, Application, and region.

The Mono Vaccines (Epstein - Barr virus) Market is segmented on the basis of age group, and region

On basis of age the global mono vaccines (Epstein-Barr virus) market has been segmented into adult, and pediatrics

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Mono Vaccines (Epstein - Barr virus) Market Regional Insights

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Mono Vaccines (Epstein - Barr virus) Market report based on Age group and region:

Mono Vaccines (Epstein - Barr virus) Market, By Age Group:

• Adult
• Pediatrics

Mono Vaccines (Epstein - Barr virus) Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Mono Vaccines (Epstein - Barr virus) Market includes, GlaxoSmithKline (GSK), Merck & Co., Inc., Johnson & Johnson, Moderna Inc., Pfizer Inc, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Novavax, Inc., Henogen SA

• GlaxoSmithKline (GSK) *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck & Co., Inc.
• Johnson & Johnson
• Moderna Inc.
• Pfizer Inc
• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Novavax, Inc.
• Henogen SA

“*” marked represents similar segmentation in other categories in the respective section